Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Executives Visit China’s Ministry of Science and Technology To Discuss Biotech Plans

This article was originally published in PharmAsia News

Executive Summary

Liu Yan-Hua, vice minister of China's Ministry of Science and Technology, recently met top executives from GSK, including Abbas Hussain, President of Emerging Markets, and Jean Stéphenne, President and General Manager of GSK Biologicals. China's investment in biotechnology R&D, which includes biopharmaceuticals, will reach RMB 10 billion under its Eleventh Five-Year Plan (2006-2011). The Ministry of Science and Technology encourages MNCs to collaborate in these R&D plans, with the aim of developing drugs that guarantee quality and affordability for China's large population with diverse economic levels. GSK is planning to invest in vaccine R&D and introduce adjuvant technology for influenza vaccine and cervical cancer vaccine to the country. (Click here for more - Chinese language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071528

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel